Adenovirus Serotype 5 Vectors with Tyr3-Octreotate Modified as a Virulytic Oncotherapy Agent in AGS Cells

  • Najmeh Yarkeh Salkhori Department of Microbiology, Faculty of Basic Sciences, Tehran North Branch, Islamic Azad University, Tehran, IR Iran
  • Taghi Naserpour Farivar Cellular and Molecular Research Center, Qazvin University of Medical Sciences, Qazvin, IR Iran
  • Jamileh Noroozi Department of Microbiology, Faculty of Basic Sciences, Tehran North Branch, Islamic Azad University, Tehran, IR Iran
  • Reza Najafipour Cellular and Molecular Research Center, Qazvin University of Medical Sciences, Qazvin, IR Iran
  • Parviz Pakzad Department of Microbiology, Faculty of Basic Sciences, Tehran North Branch, Islamic Azad University, Tehran, IR Iran
Keywords: Adenovirus, Oncolytic viruses, tyr3-octreotate, AGS

Abstract

Background: Oncolytic viral therapy is known as a new promising strategy to treat cancer. Oncolytic viruses (OVs) can replicate in cancer cells, and beside this primary effect, OVs can also stimulate the immune system. Moreover, Adenovirus serotype 5 (Ad5) is widely used as an oncolytic agent for cancer therapy. The present study aimed to make a change in the adenovirus fiber area.

Methods: The tyr3-octreotate sequence was inserted into the HI-loop in the adenovirus fiber knob.  In addition, recombinant virus was transferred to the HEK-293 packaging cells using the calcium phosphate method; therefore, the new virus was prepared. Accordingly, virus titer was calculated using the TCID50 method. Afterward, recombinant adenovirus and wild-type 5 strain were transferred to perform against human adenocarcinoma gastric cell line (AGS). Subsequently, they were evaluated for cytopathic effects, and the manipulated virus was then confirmed Using PCR and sequencing.

Results & Conclusions: In this regard, the obtained results showed that the recombinant adenovirus has a greater ability in infecting AGS cells compared to the wild-type adenovirus. Our data suggest that, modification of Ad5 with tyr3-octreotate expands its usage as an oncolytic agent against the AGS cells.

Published
2020-09-17
Section
Microbiology, Virology and Immunology